Additionally, while our findings suggest a potential therapeutic role for PPARδ antagonists in mitigating inflammation, further preclinical and clinical investigations are warranted to elucidate the efficacy and safety of such interventions in TB patients, especially those with concomitant diabetes. The gene discussed is PPARD; the disease is tuberculosis.